These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 9042907

  • 1. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes?
    Serova OM, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart YY, Goldgar D, Narod SA, Lynch HT, Lenoir GM.
    Am J Hum Genet; 1997 Mar; 60(3):486-95. PubMed ID: 9042907
    [Abstract] [Full Text] [Related]

  • 2. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
    Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H.
    Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
    [Abstract] [Full Text] [Related]

  • 3. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
    Ganguly T, Dhulipala R, Godmilow L, Ganguly A.
    Hum Genet; 1998 May; 102(5):549-56. PubMed ID: 9654203
    [Abstract] [Full Text] [Related]

  • 4. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N, Miyoshi Y, Yoneda K, Shiba E, Sekihara Y, Kinoshita M, Noguchi S.
    Int J Cancer; 2001 Jan 01; 91(1):83-8. PubMed ID: 11149425
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
    Santarosa M, Dolcetti R, Magri MD, Crivellari D, Tibiletti MG, Gallo A, Tumolo S, Della Puppa L, Furlan D, Boiocchi M, Viel A.
    Int J Cancer; 1999 Sep 24; 83(1):5-9. PubMed ID: 10449599
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
    Rutter JL, Smith AM, Dávila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP.
    Hum Mutat; 2003 Aug 24; 22(2):121-8. PubMed ID: 12872252
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mutation analysis of BRCA1 and BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in male breast cancer.
    Balci A, Huusko P, Pääkkönen K, Launonen V, Uner A, Ekmekçi A, Winqvist R.
    Eur J Cancer; 1999 May 24; 35(5):707-10. PubMed ID: 10505028
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL, Lee MK, Mefford HC, Argonza RH, Morrow JE, Hull J, Dann JL, King MC.
    Am J Hum Genet; 1997 May 24; 60(5):1031-40. PubMed ID: 9150150
    [Abstract] [Full Text] [Related]

  • 14. Mutation analysis of the BRCA1 and BRCA2 genes results in the identification of novel and recurrent mutations in 6/16 flemish families with breast and/or ovarian cancer but not in 12 sporadic patients with early-onset disease. Mutations in brief no. 224. Online.
    Claes K, Machackova E, De Vos M, Mortier G, De Paepe A, Messiaen L.
    Hum Mutat; 1999 May 24; 13(3):256. PubMed ID: 10090482
    [Abstract] [Full Text] [Related]

  • 15. Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
    Essioux L, Girodet C, Sinilnikova O, Pagès S, Eisinger F, de Résende S, Maugard C, Lanoë D, Longy M, Bignon YJ, Sobol H, Bonaïti-Pellié C, Stoppa-Lyonnet D.
    Am J Med Genet; 1998 Sep 23; 79(3):175-83. PubMed ID: 9788557
    [Abstract] [Full Text] [Related]

  • 16. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.
    Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA.
    Am J Hum Genet; 1998 Nov 23; 63(5):1341-51. PubMed ID: 9792861
    [Abstract] [Full Text] [Related]

  • 17. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
    Cui J, Antoniou AC, Dite GS, Southey MC, Venter DJ, Easton DF, Giles GG, McCredie MR, Hopper JL.
    Am J Hum Genet; 2001 Feb 23; 68(2):420-31. PubMed ID: 11133358
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.